<DOC>
	<DOCNO>NCT00072670</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy trabectedin ( ET-743 ) adult male participant advance metastatic ( spread cancer cell one part body another ) prostate cancer .</brief_summary>
	<brief_title>A Phase 2 Study Trabectedin ( Yondelis ) Adult Male Participants With Advanced Prostate Cancer</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , non-randomized , multi-center Phase 2 study adult male participant advance metastatic prostate cancer . The study consist 3 part : Screening ( consist 14 day study commences Day -1 ) ; Treatment ( consist 4-week dose cycle wherein trabectedin administer intravenously dose either 0.58 milligram per square meter [ mg/m^2 ] weekly 3-hour infusion , 1.5 mg/m^2 1.2 mg/m^2 every three week 24-hour infusion ) ; Follow-up ( survival first dose trabectedin ) . Participants discontinue study treatment disease progression unacceptable toxicity unless , Investigator 's opinion , deem participant continue derive benefit trabectedin . Efficacy evaluate primarily decline prostate-specific antigen ( substance blood measure check prostate cancer ) 72 hour therapy Day 1 . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate Radiographically document metastatic disease Surgical chemical castration Prostatespecific antigen great equal ( &gt; = ) 5 nanogram per milliliter ( ng/ml ) Eastern Cooperative Oncology Group performance status 0 , 1 , 2 Androgen Independent disease Treatment chemotherapy radiation therapy terminate least 4 week study entry Treatment extensive external beam radiation therapy radionuclide therapy within 6 week study entry ( palliative radiation involve less 20 percent bone marrow reserve must complete least 4 week study entry ) Participant employ adequate contraception Other serious illness medical condition : Uncontrolled congestive heart failure history myocardial infection active angina pectoris within six month precede registration ; active infectious process ; chronic active liver disease , include chronic Hepatitis B , chronic Hepatitis C , cirrhosis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Advanced prostate cancer</keyword>
	<keyword>Metastatic prostate cancer</keyword>
	<keyword>Trabectedin</keyword>
	<keyword>Yondelis</keyword>
	<keyword>ET-743</keyword>
</DOC>